The venture capital fund formed and still funded by SAP has renamed itself to reflect its independent status.

Rigontec, which develops RNA-based immunotherapeutics for the treatment of cancer, has raised $11.9m in a series A round featuring High-Tech Gruenderfonds.

Biotherapeutics company Bicycle Therapeutics has raised $32m in a series B round featuring pharmaceutical companies GlaxoSmithKline, Novartis and Astellas.

Edinburgh spin-out pureLifi is about to start selling its next-generation product.

Manchester University spin-out has been seeing its revenue fall this year.

Mobile payment service Inventorum is set to further develop its product with $5.1m in series A funding provided by investors including High-Tech Gruenderfonds.

Andy Tupholme hs joined investment firm Greencoat Capital, where he will work with the firm's $200m ESB Novusmodus fund, which is backed by utility ESB.

Alzheimer's drug developer Probiodrug, the backers of which include Biogen Idec, has set the range for a proposed initial public offering in the Netherlands.

SpeedInvest II will total $63m.

Leiden spin-out Mimetas secures investment from Dutch venture capitalists.